Answers are grounded in this paper and cite their sources.
Case report shows efficacy and safety of Inebilizumab treatment in refractory myasthenia gravis, suggesting a new option for management.
To report the efficacy and safety of the first rescue treatment of refractory myasthenia gravis patient with Inebilizumab (CD19 monoclonal antibody).
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: